Ottawa Hospital Cancer Centre, Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON, Canada.
Lancet Oncol. 2011 Aug;12(8):815-24. doi: 10.1016/S1470-2045(10)70245-X. Epub 2010 Dec 10.
Adenoid cystic carcinomas (ACC) are rare cancers usually arising in the salivary glands. Once metastatic, the natural history can vary; some patients with indolent cancer remain asymptomatic for long periods, whereas others have rapidly progressive disease. Chemotherapy is generally reserved for the palliative treatment of symptomatic locally recurrent or metastatic disease that is not amenable to further surgery or radiation. Prospective trials of chemotherapy in advanced ACC are limited, and the optimum regimen is unclear. The aim of this systematic review is to summarise and rate the quality of trials assessing chemotherapy for treatment of ACC, by use of the European Lung Cancer Working Party scoring system. Endpoints evaluated include tumour response and rates of symptomatic improvement. 34 trials involving 441 patients are included. We give evidence-based recommendations for management of ACC with chemotherapy, along with considerations for the design of future clinical trials in this disease.
腺样囊性癌(ACC)是一种罕见的癌症,通常发生在唾液腺。一旦转移,其自然病程可能会有所不同;一些惰性癌症患者可能会长期无症状,而另一些患者则会出现快速进展的疾病。化疗通常是为了缓解局部复发性或转移性疾病的症状而进行的,这些疾病不适合进一步手术或放疗。晚期 ACC 的化疗前瞻性试验有限,最佳方案尚不清楚。本系统评价的目的是使用欧洲肺癌工作组评分系统,总结和评估评估化疗治疗 ACC 的试验的质量。评估的终点包括肿瘤反应和症状改善的发生率。共纳入 34 项涉及 441 例患者的试验。我们为 ACC 的化疗管理提供循证建议,并考虑在该疾病的未来临床试验中进行考虑。